Treatment of myoclonic-atonic epilepsy caused by SLC2A1 de novo mutation with ketogenic diet: A case report
- PMID: 31045803
- PMCID: PMC6504322
- DOI: 10.1097/MD.0000000000015428
Treatment of myoclonic-atonic epilepsy caused by SLC2A1 de novo mutation with ketogenic diet: A case report
Abstract
Rationale: The SLC2A1 gene encodes glucose transporter 1 on blood-brain barrier, which plays an important role in the energy supply for neurons. Mutations in SLC2A1 gene can cause many clinical syndromes, including glucose transporter type 1 deficiency syndrome and many types of epilepsy syndromes such as childhood absence epilepsy and myoclonic-atonic epilepsy, etc. Ketogenic diet has been proved to be very effective on those cases. Clinically, SLC2A1 gene mutations are quite rare.
Patient concerns: Repeated unconsciousness and bilateral limb weakness lasted for 3 years.
Diagnoses: Myoclonic-atonic epilepsy.
Lessons: After taking whole exome sequencing, we found out that there is a de novo insertion mutation in the patient's SLC2A1 gene, leading to frameshift. As a result, ketogenic diet (2:1, 4 times a day) was used as the treatment. As for the patient, total calories intake per day was controlled at 1190 kcal. The calories per kg per day were 66.11 kcal/kg. The amount of ketone bodies was controlled at 2 to 3 mmol/L and the concentration of plasma glucose was controlled at 4 to 5 mmol/L.
Outcomes: After the launch of ketogenic diet, the patient has been seizure free for nearly a year and stopped all his antiepileptic drugs.
Conclusion: Our case suggests that gene examination is very important part of the diagnosis of epilepsy etiology and epilepsy syndromes. Ketogenic diet should be considered as the first line therapy with SLC2A1 gene mutations.
Conflict of interest statement
The authors declare that they have no competing interest.
Figures
Similar articles
-
SLC6A1 Mutation and Ketogenic Diet in Epilepsy With Myoclonic-Atonic Seizures.Pediatr Neurol. 2016 Nov;64:77-79. doi: 10.1016/j.pediatrneurol.2016.07.012. Epub 2016 Jul 28. Pediatr Neurol. 2016. PMID: 27600546 Free PMC article.
-
Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy.Arch Neurol. 2011 Sep;68(9):1152-5. doi: 10.1001/archneurol.2011.102. Epub 2011 May 9. Arch Neurol. 2011. PMID: 21555602
-
The glucose transporter type 1 (Glut1) syndromes.Epilepsy Behav. 2019 Feb;91:90-93. doi: 10.1016/j.yebeh.2018.06.010. Epub 2018 Jul 31. Epilepsy Behav. 2019. PMID: 30076047 Review.
-
The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome.Epilepsia. 2015 Dec;56(12):e203-8. doi: 10.1111/epi.13222. Epub 2015 Nov 5. Epilepsia. 2015. PMID: 26537434
-
Glucose transporter type 1 deficiency due to SLC2A1 gene mutations--a rare but treatable cause of metabolic epilepsy and extrapyramidal movement disorder; own experience and literature review.Dev Period Med. 2015 Oct-Dec;19(4):454-63. Dev Period Med. 2015. PMID: 26982753 Review.
Cited by
-
Solute carrier transporter disease and developmental and epileptic encephalopathy.Front Neurol. 2022 Nov 7;13:1013903. doi: 10.3389/fneur.2022.1013903. eCollection 2022. Front Neurol. 2022. PMID: 36419532 Free PMC article. Review.
-
Clinical and Genetic Characteristics of Chinese Children With GLUT1 Deficiency Syndrome: Case Report and Literature Review.Front Genet. 2021 Nov 22;12:734481. doi: 10.3389/fgene.2021.734481. eCollection 2021. Front Genet. 2021. PMID: 34880899 Free PMC article.
-
Exome sequencing in paediatric patients with movement disorders.Orphanet J Rare Dis. 2021 Jan 15;16(1):32. doi: 10.1186/s13023-021-01688-6. Orphanet J Rare Dis. 2021. PMID: 33446253 Free PMC article.
-
A Novel Intronic Variant in SLC2A1 Gene in a Saudi Patient with Myoclonic Epilepsy.J Epilepsy Res. 2020 Jun 30;10(1):40-43. doi: 10.14581/jer.20007. eCollection 2020 Jun. J Epilepsy Res. 2020. PMID: 32983954 Free PMC article.
References
-
- Escary J, Cecillon M, Maciazek J, et al. Mutational analysis of GLUT1 (SLC2A1) in glut-1 deficiency syndrome; dong wang; pamela kranz-eble; darryl C. De vivo; (Article was originally published in human mutation 16:224-231, 2000). Hum Mutat 2000;16:527. - PubMed
-
- De Vivo DC, Trifiletti RR, Jacobson RI, et al. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991;325:703–9. - PubMed
-
- Klepper J. GLUT1 deficiency syndrome in clinical practice. Epilepsy Res 2012;100:272–7. - PubMed
-
- Koch H, Weber YG. The glucose transporter type 1 (Glut1) syndromes. Epilepsy Behav 2019;91:90–3. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
